Company intelligence / Profile preview

FreeOx Biotech

Ownership: Private
Development stage: Phase 3

Overview

Ox-01 showed a 19% increase in patients achieving good outcomes in a pre-assigned subgroup of a 421-patient Phase IIb clinical trial (URICO-ICTUS). A study found that 42% of female stroke patients treated with clot busters and uric acid had little or no disability after 90 days compared with 29% treated with clot busters and placebo.

Therapeutic areas: Neurology
Modalities: Small molecules (Uric Acid-based formulations)Liposomal formulations
Industry: Biotech

Drug pipeline

2 assets

Ox-01

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

National Institute of Neurological Disorders and Stroke (NINDS)

Beyond the preview

Go deeper on FreeOx Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FreeOx Biotech.

Explore the full profile